机译:具有含有玻璃体内贝伐单抗或Ranibizumab治疗的前疗疗法视网膜病变的患儿进行渐进式视网膜脱离
Harvard Med Sch Massachusetts Eye &
Ear Infirm Boston MA USA;
Chang Gung Mem Hosp Dept Ophthalmol Taoyuan Taiwan;
Natl Inst Mother &
Child Hlth Alessandrescu Ruses Dept Ophthalmol Bucharest Romania;
Univ Illinois Coll Med Retina Serv Dept Ophthalmol Illinois Eye &
Ear Infirm Chicago IL USA;
Associated Retinal Consultants Royal Oak MI USA;
Florida Retina Inst Jacksonville FL USA;
Associated Retinal Consultants Royal Oak MI USA;
Associated Retinal Consultants Royal Oak MI USA;
Associated Retinal Consultants Royal Oak MI USA;
Associated Retinal Consultants Royal Oak MI USA;
anti-VEGF; bevacizumab; ranibizumab; retinal detachment; retinopathy of prematurity;
机译:具有含有玻璃体内贝伐单抗或Ranibizumab治疗的前疗疗法视网膜病变的患儿进行渐进式视网膜脱离
机译:在玻璃体内注射兰尼单抗治疗区域1加上早产儿视网膜病变后,视网膜发作延迟。
机译:在激光光凝治疗早熟的1型术治疗后的短期视网膜脱离风险与术治疗早产儿
机译:通过分析早产儿血管基底图像血管结构的血管结构视网膜病变的计算机辅助诊断
机译:高碳酸血症参与视网膜血流和新生血管形成的新机制:对早产儿及以后的视网膜病变的影响。
机译:玻璃体腔注射贝伐单抗治疗I区侵袭性早发性早产儿视网膜病的婴儿视网膜血管变化的系列评估
机译:玻璃体内雷珠单抗和贝伐单抗治疗早产儿视网膜病变的比较